Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Oncotelic Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
1.74
0.07
Research and development
8.76
10.5
0.65
1.37
4.3
3.66
0.76
0.06
0
General and administrative
5
3.37
0.06
2.94
5.02
5.47
4.85
0.57
0.38
3.18
Operating expenses
13.8
13.8
0.71
4.31
9.33
9.13
9.72
6.72
3.58
3.19
Operating income
-13.8
-13.8
-0.71
-4.31
-7.58
-9.13
-9.72
-6.65
-3.58
-3.19
Interest expense
0.75
2
2
2.97
1.04
Interest income
0.11
0.04
0.02
0
Other non-operating income
-0
-0.01
-0
-2.33
-2.39
-1.39
14.4
-1.56
-1.2
364
Pre-tax income
-4.78
361
Income tax
112
Net income to minority interests
-0.47
-1.13
-0.42
-0.3
-0.26
-0.25
Net income
-13.7
-13.8
-0.71
-6.64
-9.5
-9.39
5.09
-7.9
-4.52
249
EBITDA
-13.7
-13.8
-0.71
-4.3
-7.55
-9.12
EPS, basic
-0.87
-0.89
-0.12
-0.11
-0.11
-0.03
0.01
-0.02
0.01
0.59
EPS, diluted
-0.87
-0.89
-0.12
-0.11
-0.11
-0.03
0.01
-0.02
-0.01
0.59
Shares, basic (weighted)
15.5
15.5
6.14
60
88.1
303
384
384
404
421
Shares, diluted (weighted)
15.5
15.5
6.14
60
88.1
303
457
396
404
422
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
3.54
1.12
0
0.08
0.47
0.57
0.24
0.17
0.09
0.09
Short-term investments
8.51
Receivables
0.15
0.02
0.02
0.02
0.02
0.02
0.05
Other current assets
0.08
0.02
0.01
1.04
Total current assets
14.1
1.14
0
0.27
0.62
0.63
0.3
0.27
0.13
1.2
Property, plant and equipment
0.01
0
0.05
Goodwill
21.1
21.1
21.1
12.1
5.99
2.79
2.79
Intangible assets
0.98
0.92
0.87
0.82
Long-term investments
1.77
Other non-current assets
0.03
0.03
Total assets
14.1
1.17
2.75
23.7
23.7
23.6
36.1
30
26.7
393
Accounts payable
0.31
0.79
0.92
1.79
1.94
1.93
0.33
2.44
2.44
2.57
Accrued liabilities
0.26
0.8
1.16
0.78
Short-term debt
0.1
0.36
0.39
1.77
2.42
Total current liabilities
1.61
1.65
0.28
6.78
11.2
15.5
16.9
16.5
19.2
18.1
Total liabilities
1.61
1.66
0.28
6.78
11.2
15.5
16.9
18.4
19.2
131
Paid-in capital
291
292
7.89
28.2
32.5
35.2
41.4
41.7
42.2
47.1
Retained earnings
-278
-292
-5.49
-12.1
-21.6
-31
-25.9
-33.5
-38
211
Shareholders' equity
12.5
-0.48
2.46
16.9
11.8
7.96
19.4
12.1
8.25
263
Minority interests
0.71
0.2
-0.22
-0.52
-0.77
-1.03
Total equity
12.5
-0.48
2.46
16.9
12.5
8.16
19.2
11.6
7.48
262
Total liabilities and equity
14.1
1.17
2.75
23.7
23.7
23.6
36.1
30
26.7
393
Shares outstanding
15.5
15.5
6.84
84.1
90.6
375
392
399
407
443
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-13.7
-13.8
-2.74
-6.64
-9.97
-10.5
4.68
-8.21
-4.78
249
Depreciation and amortization
0.02
0.01
0
0.01
0.04
0.01
Stock-based compensation
0.8
0.84
0.08
0.34
2.15
0.76
0.9
0
0
2.38
Deferred income tax
112
Change in payables
-0.49
0.04
0.04
0.62
0.68
0.21
0.87
-0.07
0.29
0.1
Cash from operations
-15.2
-10.9
-0.24
-2.28
-2.81
-4.43
-1.45
-1.32
-0.74
-1.38
Purchases of investments
-21
Cash from investing
-8.51
8.51
0.19
Debt issued
0.25
Debt repaid
-0.1
Stock issued
0.24
0.08
0.42
0.16
Cash from financing
0.24
2.17
3.22
4.53
1.13
1.25
0.66
1.39
Net change in cash
-23.8
-2.42
-0
0.08
0.41
0.09
-0.33
-0.07
-0.08
0
Interest paid
0.05
0.3
0.4
0.39
0.37
0.37
Income taxes paid
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.02 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
93.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
62.7%
Net income / average total assets.
Return on invested capital (ROIC)
-1.7%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Net income CAGR, 3y
265.7%
Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 3y
289.3%
Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
3,084.0%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
138.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
86.1%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
1,373.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
121.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
75.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
4.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
-2.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
36.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.08x
Current assets / current liabilities.
Quick ratio
0.01x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.01x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.00
Cash from operations / diluted weighted shares.
Book value per share
$0.58
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
0.04x
Market cap / net income. Only when net income is positive.
P/B
0.04x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.04x
Market cap / tangible book value, when positive.
Earnings yield
2,245.0%
Net income / market cap (the inverse of P/E).
PEG
0.00x
P/E / EPS growth per year over 3 years (in percent). Only when both are positive.
Was Oncotelic Therapeutics, Inc. profitable in fiscal 2025?
Yes. Net income was $249.3M, a net margin of -.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.